This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bionomics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Bionomics şirketinin toplam hissedar öz sermayesi A$47.7M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$56.3M ve A$8.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$30.70m
Eşitlik	AU$47.72m
Toplam yükümlülükler	AU$8.59m
Toplam varlıklar	AU$56.31m

Son finansal sağlık güncellemeleri

Recent updates

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Jun 14

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

Feb 23

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Sep 14

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Nov 15

Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?

Dec 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BNO 'nin kısa vadeli varlıkları ( A$33.1M ) kısa vadeli yükümlülüklerini ( A$3.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: BNO şirketinin kısa vadeli varlıkları ( A$33.1M ) uzun vadeli yükümlülüklerini ( A$4.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BNO borçsuzdur.

Borcun Azaltılması: BNO şirketinin 5 yıl önce borç/öz sermaye oranı 63.9% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BNO şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: BNO serbest nakit akışı her yıl % 9 1.7 yıl yetecek nakit akışına sahip olacaktır.

This company listing is no longer active

Bionomics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

New 90-day high: AU$0.39

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

New 90-day high: AU$0.22

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - AU$0.0082 loss per share

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin